CL2021002877A1 - Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos - Google Patents

Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos

Info

Publication number
CL2021002877A1
CL2021002877A1 CL2021002877A CL2021002877A CL2021002877A1 CL 2021002877 A1 CL2021002877 A1 CL 2021002877A1 CL 2021002877 A CL2021002877 A CL 2021002877A CL 2021002877 A CL2021002877 A CL 2021002877A CL 2021002877 A1 CL2021002877 A1 CL 2021002877A1
Authority
CL
Chile
Prior art keywords
compositions
kcnt1
neurological disorders
gene inhibitors
disease
Prior art date
Application number
CL2021002877A
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Andrew Mark Griffin
Paul S Charifson
Kiran Reddy
Michael Kristopher Mathieu Kahlig
Brian Edward Marron
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of CL2021002877A1 publication Critical patent/CL2021002877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida, en parte, a compuestos y composiciones útiles para prevenir y / o tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con una excitabilidad neuronal excesiva y / o una mutación de ganancia de función en un gen (por ejemplo, KCNT1). También se proporcionan en el presente documento métodos para tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con una excitabilidad neuronal excesiva y / o una mutación de ganancia de función en un gen tal como KCNT1.
CL2021002877A 2019-05-03 2021-11-02 Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos CL2021002877A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28

Publications (1)

Publication Number Publication Date
CL2021002877A1 true CL2021002877A1 (es) 2022-08-12

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002877A CL2021002877A1 (es) 2019-05-03 2021-11-02 Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos

Country Status (16)

Country Link
US (1) US20220259193A1 (es)
EP (1) EP3962481A4 (es)
JP (1) JP2022531388A (es)
KR (1) KR20220016086A (es)
CN (1) CN114269340A (es)
AU (1) AU2020267356A1 (es)
BR (1) BR112021022067A2 (es)
CA (1) CA3139063A1 (es)
CL (1) CL2021002877A1 (es)
CO (1) CO2021016471A2 (es)
EC (1) ECSP21087884A (es)
IL (1) IL287768A (es)
MX (1) MX2021013421A (es)
PE (1) PE20220016A1 (es)
SG (1) SG11202112158YA (es)
WO (1) WO2020227101A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2023239839A1 (en) * 2022-06-08 2023-12-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2009544625A (ja) * 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
ES2665619T3 (es) * 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
JP6668329B2 (ja) * 2015-03-25 2020-03-18 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
US11731966B2 (en) * 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
CA3139063A1 (en) 2020-11-12
PE20220016A1 (es) 2022-01-11
SG11202112158YA (en) 2021-12-30
JP2022531388A (ja) 2022-07-06
ECSP21087884A (es) 2022-01-31
EP3962481A4 (en) 2023-03-22
WO2020227101A1 (en) 2020-11-12
CN114269340A (zh) 2022-04-01
BR112021022067A2 (pt) 2022-05-17
MX2021013421A (es) 2022-02-11
AU2020267356A1 (en) 2022-01-06
CO2021016471A2 (es) 2022-04-08
EP3962481A1 (en) 2022-03-09
US20220259193A1 (en) 2022-08-18
KR20220016086A (ko) 2022-02-08
IL287768A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
CL2021002877A1 (es) Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos
CL2021002876A1 (es) Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX2020003961A (es) Uso de inhibidores de p38 para reducir la expresion de dux4.
BR112018071560A2 (pt) compostos e métodos para tratar condições neurológicas e cardiovasculares
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
CL2021003374A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
BR112022019041A2 (pt) Inibidores de kcnt1 e métodos de uso
ECSP19021843A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
BR112017025263A2 (pt) método para o tratamento de doença neurológica
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
MX2019000594A (es) Factor anti-secretor 17.
BR112022017191A2 (pt) Inibidores de kcnt1 e métodos de uso
CO2022001412A2 (es) Composiciones y métodos para el tratamiento de la enfermedad de sanfilippo y otros trastornos
CO2023016136A2 (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)